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1. Introduction
Calcific aortic valve disease represents the predominant pathology of tricuspid (trileaflet) and
bicuspid aortic valves in developed countries (Ladich et al., 2011). Accounting for approxi‐
mately half of anatomically isolated aortic stenosis and 25 percent of patients with aortic
regurgitation (Roberts, 1970), calcific bicuspid aortic valves requiring surgical intervention
present at least two decades earlier than the tricuspid counterpart (Ward, 2000). Mechanisms
important in cardiac and organ development — notably, the Notch pathway — have emerged
as central players recapitulated and reused during the pathogenesis of calcific aortic valve
disease, and support also a common etiology for bicuspid aortic valve and aortic valve
calcification (Garg et al., 2005) (Table 1). Active engagement of inflammatory, remodeling,
neovascularization and osteogenic (Aikawa et al., 2007a; Aikawa et al., 2007b; Miller et al.,
2010; Rajamannan et al., 2003) pathways has conceptually replaced ‘degeneration’ in calcific
aortic valve disease pathogenesis and progression (Dweck et al., 2012). Moreover, these
pathways invoke similar mechanisms during cardiac morphogenesis. Dysregulated Notch
activity has also been reported in vascular inflammation, macrophage activation (Fung et al.,
2007), cardiometabolic disorder, and vascular and aortic valve calcification (Fukuda et al.,
2012). Preclinical studies suggest that specific blockade of Notch ligand–receptor signaling
potently suppresses vascular calcification and calcific aortic valve disease (Fukuda et al.,
2012). In this chapter, we review the mechanisms of Notch signaling, aortic valve dysmor‐
phology pertinent to accelerated valve calcification, and discuss the pathways involving Notch
that lead to aortic valve calcification and disease.
© 2013 Fung and Aikawa; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Role in cardiac and aortic valve development Role in aortic valve calcification
NOTCH1 cardiac morphogenesis inhibits calcification
Hey1/2 downstream effector of Notch inhibits action of
BMP2
inhibits calcification, decreases
ostepontin
BMP2 coordination of cardiac patterning and EMT required
for valve formation
promotes calcification
Sox9 increased by Hey2 and mediates chondrogenesis suppresses osteogenesis
Runx2 repressed by NOTCH1 and Hey1/2 promotes calcification
JAG1 boundary definition in myocardium; vasculogenesis inhibits calcification
DLL4 formation of heart fields and boundary definition in
endocardium; vasculogenesis
neovascularization (angioneogenesis) &
hemorrhage leading to calcific aortic
valve disease
Table 1. Major components of the Notch1-Hey-BMP2 axis and their actions in cardiac and aortic valve development,
and in aortic valve calcification. BMP, bone morphogenetic protein. DLL4, Delta-like 4. JAG1, Jagged1.
2. Notch signaling
The human Notch receptor family comprises four members, Notch1 through Notch4, ex‐
pressed as transmembrane molecules on the cell surface of neighboring cells that enable
canonical signaling in a contact-dependent manner (Bray, 2006; Kopan and Ilagan, 2009).
Canonical Notch signaling describes the ‘classic’ interaction between membrane-bound
receptors and ligands expressed on the surface of neighboring (signaling and receiving) cells,
whereas non-canonical signaling encompasses a diverse group of structurally unrelated
ligands that contribute to the pleiotropic effect of Notch signaling (Kopan and Ilagan, 2009).
In mammals, five members of the Delta-Serrate-LAG-2 (DSL) family have the capacity to
activate or modify canonical Notch signaling — Delta-like 1 (Dll1), Dll3, Dll4, Jagged1, and
Jagged2. Interaction between Notch receptor and ligand is tightly controlled, and the signaling
outcome is determined by the receptor:ligand ratio (Artavanis-Tsakonas and Muskavitch,
2010; Gibert and Simpson, 2003; Heitzler and Simpson, 1991; Wilkinson et al., 1994) that
critically determines asymmetry in cell fate and development of neighboring cells. This
interaction between receptor and ligand can be modified posttranslationally through Notch
glycosylation by lunatic, manic and radical glycosyltransferases (Bray, 2006). The receptor:li‐
gand ratio is dependent on the differential expression of competing ligands on neighboring
cells in trans, as opposed to cis interaction through which receptor and ligand expressed on
the same cell can also modulate Notch signaling. The complexity of receptor–ligand interaction
is further increased by the requirement of heterodimerization of the receptor (Kopan and
Ilagan, 2009). Canonical interaction between Notch receptor and ligand leads to two sequential
cleavage events at site 2 (S2) and S3. S2 is a ‘permissive’ extracellular juxtamembrane cleavage
by a disintegrin and metalloprotease 17 (ADAM17, known also as tumor necrosis factor-α
converting enzyme/TACE) and/or ADAM10 (Artavanis-Tsakonas and Muskavitch, 2010;
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Bray, 2006), whereas S3 is executed by γ-secretase, a protease with many substrates (McCarthy
et al., 2009; Wakabayashi and De Strooper, 2008). S1 cleavage is carried out by a furin-like
convertase occurring posttranslationally in the trans-Golgi apparatus before translocation of
the nascent Notch receptor to the cell surface (Bray, 2006; Kopan and Ilagan, 2009). Following
S3 cleavage, the Notch intracellular domain is liberated and enters the nucleus to form a
transcription activational complex with the transcriptional factor RBP-Jκ, and the transcrip‐
tional coactivator Mastermind to promote target gene transcription (Bray, 2006; Kopan and
Ilagan, 2009). Targets indicative of Notch activity include the basic-helix-loop-helix genes of
the hairy and enhancer of split (HES) and the hairy-related (HRT or Hey) family (Bray, 2006;
Kopan and Ilagan, 2009).
Functionality of Notch signaling components is highly context-dependent and conventionally
requires cell-to-cell contact to specify cell fate, differentiation, growth, proliferation, survival
and apoptosis (Bray, 2006; Fiuza and Arias, 2007; Guruharsha et al., 2012). Interaction between
Notch receptor and ligand on adjacent cells results in asymmetric signal transduction, leading
to potentially divergent cell fate decision, phenotypic development and growth (Bray, 2006;
Kopan and Ilagan, 2009).
3. Congenital aortic valve disease
3.1. Notch dysfunction in aortic valve anomalies and other congenital heart diseases
Congenital aortic valve anomalies frequently associate with other abnormalities in neighbor‐
ing structures, including the aortic root (e.g. dilatation, aneurysm), aorta (e.g. coarctation of
aorta), ventricular outflow tract (e.g. septal defect, transposition of great vessels), and/or
coronary arteries (e.g. coronary anomalies) (Perloff, 2003; Ward, 2000). The association of
anomalies is due in part to the complexity and critical function of the endocardial cushion, and
its formation during cardiac valve and septum development (Camenisch et al., 2010).
The tight regulation of Notch signaling during murine cardiac morphogenesis, particularly of
the cardiac outflow tract and semilunar (aortic and pulmonary) valves, have been recently
reviewed in detail by de la Pompa and Epstein (de la Pompa and Epstein, 2012). The evolu‐
tionarily conserved nature of Notch across mammalian species is generally recognized to be
applicable to human. The highly coordinated action of Notch in progenitor cell proliferation
and differentiation is instrumental during development. Earliest signs of cardiac morphogen‐
esis occur with formation of the cardiac crescent by midline fusion of first and second heart
fields that feature expression of Notch1, Dll4 and Jagged1 in the primitive endocardium (de
la Pompa and Epstein, 2012; del Monte et al., 2007; Duarte et al., 2004). Continuing cell
proliferation and development leads to the generation of the heart tube, consisting of an outer
myocardial layer, middle cardiac jelly of extracellular matrix, and an inner endocardial
endothelium (Camenisch et al., 2010; de la Pompa and Epstein, 2012). Demarcation of boun‐
dary and tissue layers is marked by expression of Jagged1 limited to the myocardial layer, and
Dll4, Notch1, Notch2 and Notch4 in the endocardium. The heart tube gradually undergoes a
complex morphologic change with a rightward bend, converting the anterior-posterior
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polarity of the heart tube into a right-left (R-) loop. As the looped heart further develops, the
valve territories of the atrioventricular canal (AVC) and outflow tract (OFT) are demarcated.
The AVC and OFT cushions become the sites for formation of the mitral and aortic valves,
respectively, in the left ventricle and the tricuspid and pulmonary valves in the right ventricule
(Person et al., 2005). Contribution of endocardium-derived mesenchyme to the development
of AVC and OFT valve primordia diverge as the neural crest contribute additionally to the
development of the OFT valve primordium (de la Pompa and Epstein, 2012; Zhang et al., 2010).
At this stage of development, Jagged1 expression is present in the endocardium and chamber
myocardium, whereas expression of Dll4 and Notch1 localizes to the valve and atrial endo‐
cardium. Here, Notch coordinates cardiac patterning through regulation of the Notch-Hey-
Bmp2 axis (MacGrogan et al., 2011). Bmp2, or bone morphogenetic protein 2, is responsible
for AVC specification together with Tbx2/3, members of the T-box transcription factor family
with crucial roles in cardiac development (de la Pompa and Epstein, 2012; Ma et al., 2005).
Tbx2 is repressible by Tbx20, which has regulatory function in ion channel expression (Shen
et al., 2011). Importantly, TBX20 nonsense and missense germline mutations result in complex
septal, chamber and valvular anomalies in human (Kirk et al., 2007). Tbx transcription factors
carry strong activation and repression domains and, especially Tbx20, interact with other
important cardiac developmental factors including Nkx2.5, Gata4, Gata5 and Tbx5 (Brown et
al., 2005; Combs and Yutzey, 2009; Kirk et al., 2007; Plageman and Yutzey, 2005; Stennard et
al., 2003). Targeted disruption of Gata5 has been demonstrated to associate with the develop‐
ment of bicuspid aortic valve in the mouse (Laforest et al., 2011), and one study on patients
with bicuspid aortic valve found that approximately 4% had rare non-synonymous mutations
within the GATA5 transcriptional activation domains (Padang et al., 2012). A functional
connection between gata5 and notch1 was reported in a zebrafish study of endoderm formation
(Kikuchi et al., 2004), and those findings may potentially be generalized to human, given the
evolutionarily conserved nature of the Notch pathway (Artavanis-Tsakonas and Muskavitch,
2010).
Cardiac valve formation begins with myocardial cells signaling to endocardial cells in the AVC
and OFT cushions to undergo epithelial-mesenchymal transformation (transition) (EMT) (de
la Pompa and Epstein, 2012). Coordinated by Notch and RBP-Jκ (del Monte et al., 2007;
Timmerman et al., 2004), Bmp2 instructs cushion endocardial cells to invade the extracellular
matrix and become the cushion mesenchyme (Hinton and Yutzey, 2011), and acting via
Snail1/2, the Notch–Hey–Bmp2/4 axis promotes EMT and subsequent completion of valve
tissue development (MacGrogan et al., 2011) (Figure 1). Interference with Notch signaling
results in abnormal development of the aortic valve and cardiac outflow tract as demonstrated
in animal studies (de la Pompa and Epstein, 2012; Garg et al., 2005; Mohamed et al., 2006; van
den Akker et al., 2012). As discussed below, BMP2 also mediates aortic valve calcification.
Bicuspid aortic valve represents one of the most common anomalies of the heart or vessels
(Roberts, 1970; Roberts et al., 2012; Ward, 2000), and its association with other anomalies is
well recognized. For instance, ~10% of relatives of patients with hypoplastic left heart syn‐
drome have bicuspid aortic valve (Loffredo et al., 2004), and aortic abnormalities such as
coarctation of aorta and interrupted aortic arch are present in 20–85% (Presbitero et al., 1987;
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Stewart et al., 1993) and ~27% (Roberts et al., 2012) of cases, respectively. Individuals with
bicuspid aortic valve consistently have dilatation of the ascending aorta (Hahn et al., 1992). As
a common variation noted by several investigators (Higgins and Wexler, 1975; Hutchins et al.,
1978), a higher incidence of left coronary arterial system dominance (defined by the presence
of the posterior descending artery arising from the left circumflex artery, as opposed to the
right coronary artery) is observed in patients with bicuspid aortic valve. The phenotypic
heterogeneity and overlap suggest common developmental mechanisms and gene networks
that closely interact; the extent of the interactions may vary depending on the penetrance of
the mutation(s), effect size of the variants, and the interaction between genes and signaling
pathway.
In a study of two unrelated families, one of which included five generations, Garg and
colleagues observed mutations in NOTCH1 that segregated with aortic valve disease, partic‐
ularly with bicuspid aortic valve and aortic valve calcification; but also, to a lesser extent, with
tetralogy of Fallot, ventricular septal defect, mitral atresia, double-outlet right ventricle, or
hypoplastic left ventricle (Garg et al., 2005). NOTCH1 is located on chromosome 9q34.3 and
encodes the 2,556-amino acid transmembrane Notch1 receptor. Affected members of one of
the families analyzed had autosomal dominant inheritance of a point mutation (R1108X)
resulting from a C-to-T transition of nucleotide 3322. Another unrelated family analyzed had
Figure 1. Diagram of a looped heart expanded to show the outflow tract (OFT) and the atrioventricular canal (AVC)
endocardial cushions where epithelial-mesenchymal transition (EMT) occurs and precedes the development of semilu‐
nar and atrioventricular valves, respectively. Factors important during cardiac EMT and valve morphogenesis are
shown. Myocardium, red; endocardium, blue; extracellular matrix, gray. Bmp, bone morphogenetic protein. Fgf, fibro‐
blast growth factor. sGC, soluble guanylyl cyclase. Tbx, T-box transcription factor. Tgf, transforming growth factor.
Adapted with permission from Elsevier.
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a single base pair deletion leading to a frameshift mutation (H1505del) at position 4515. These
mutations produced truncated transcripts that are believed to undergo nonsense-mediated
decay, supporting haploinsufficiency of NOTCH1 in the pathogenesis of congenital heart
disease (Garg et al., 2005). Of note, despite the high propensity to development of bicuspid
aortic valve and other cardiac anomalies in individuals with the NOTCH1 mutation (R1108X)
(Garg et al., 2005), aortic valve calcification was present even in a minority of family members
with the mutation who did not have bicuspid or dysmorphic aortic valves, suggesting that the
penetrance of the NOTCH1 mutation is variable (or the effects compensated for by another
Notch receptor or other mechanisms), and that maldistribution of mechanical stress alone can
not explain accelerated valve calcification in these individuals.
Mutations or abnormal copy number variants in the gene (JAG1) encoding Jagged1, a Notch
ligand, on chromosome 20p12 can cause a range of cardiovascular anomalies (McElhinney et
al., 2002; Oda et al., 1997). However, the distribution and manifestations of cardiovascular
anomalies, including the frequency of bicuspid aortic valve and calcific aortic valve disease,
differ considerably between the JAG1 and NOTCH1 mutations (Garg et al., 2005; McElhinney
et al., 2002). Although JAG1 mutation is well recognized as a primary cause of Alagille
syndome, familial as well as ‘sporadic’ tetralogy of Fallot, among other anomalies, has been
reported (Eldadah et al., 2001; Greenway et al., 2009). Tetralogy of Fallot is a syndrome that
comprises ventricular septal defect, pulmonary stenosis, right ventricular hypertrophy and an
overriding aorta, in association with aortic regurgitation in ~6% of patients (Abraham et al.,
1979). Mutations in JAG1 have been identified in 60–75% of individuals with Alagille syndrome
(Colliton et al., 2001; Li et al., 1997; Oda et al., 1997; Spinner et al., 2001), a condition charac‐
terized by cholestatic jaundice due to biliary tree anomalies, skeletal deformities, systemic
vascular malformations and aneurysms (Kamath et al., 2004), and a high frequency of right-
sided cardiovascular anomalies (62% of 200 patients) (McElhinney et al., 2002). In patients with
left-sided anomalies (22 of 200 individuals (McElhinney et al., 2002)), a comparison of those
with (n = 17) and without (n = 5) JAG1 mutation did not reveal an obvious trend favoring the
distribution nor preponderance of valvular aortic stenosis, supravalvular aortic stenosis, aortic
coarctation, or bicuspid aortic stenosis without stenosis (McElhinney et al., 2002). Those
findings suggest that aortic valve disease, such as bicuspid aortic valve and at least moderate-
severe aortic stenosis, is relatively uncommon (<5%) in patients with Alagille syndrome
(McElhinney et al., 2002), and implies that JAG1 mutation per se does not predispose to aortic
valve calcification in human, as evidenced by the paucity of left-sided abnormalities. Interest‐
ingly, although previous mouse studies have reported high lethality associated with endo‐
thelial-specific deletion of Jag1 (Benedito et al., 2009; High et al., 2008), one recent study
demonstrated a high frequency of cardiac, great vessel, coronary, and valve defects resembling
features of tetralogy of Fallot in human; and in animals, chondrogenic nodules and calcification
were observed in the aortic valve (5 of 10 transgenic animals versus 0 of 10 controls) (Hofmann
et al., 2012). The authors of the study postulated that murine Jag1 was essential to morpho‐
genesis of the interventricular septum and cardiac valves, and particularly, in valve remodel‐
ing postnatally through modulation of extracellular matrix (Hofmann et al., 2012).
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The complexity of gene-phenotype effects in human is highlighted by variable penetrance of
JAG1 mutation (e.g. G274D missense mutation) and phenotypic expression, as demonstrated
by differences in the degree of glycosylation, protein trafficking and cell-surface protein
expression given the same mutation (Lu et al., 2003). This heterogeneity is reminiscent of the
variable effects of NOTCH1 in the pathogenesis of bicuspid aortic valve and other cardiovas‐
cular anomalies (Garg et al., 2005), and epigenetic factors such as intracardiac fluid forces may
be important contributors that couple with transcription factors to affect cardiogenesis and
valve development (Hove et al., 2003; Lee et al., 2006; Vermot et al., 2009).
3.2. Aortic valve dysmorphology, bicuspid aortic valve and calcification
Anomalies of the aortic valve can be classified based on size, shape, the number of valve
leaflets, cuspal inequality, nature of commissures (e.g. unicomissural, acquired fusion), and
location of a false raphé if present (Perloff, 2003; Ward, 2000). Unicuspid, quadricuspid and
six-cuspid aortic valves occur rarely (Perloff, 2003), and associated mutations have not been
reported, unlike bicuspid aortic valves resulting from impaired Notch1 signaling (Garg et al.,
2005). Unicuspid and bicuspid aortic valves often prematurely develop valve calcification at
least two decades earlier than their normal trileaflet counterpart (Pachulski and Chan, 1993).
Although maldistribution of mechanical stress contributes to the fibrocalcific process, addi‐
tional factors apart from biomechanical forces including inflammatory and profibrotic
processes direct the differentiation of valve fibroblasts into myofibroblasts and osteoblasts that
promote osteogenesis (Dweck et al., 2012; Rajamannan et al., 2003).
Maldistribution of shear stress on valve cusps is thought to promote calcification of the aortic
valve seen in unicuspid, bicuspid, and tricuspid aortic valve with cuspal inequality (Perloff,
2003). Bicuspid aortic valve is found in 1–2% of the general population in the United States,
with a slight male predominance reported in some studies (Roberts et al., 2012; Ward, 2000).
Maldistribution of diastolic force among valve cusps and sinus attachment is thought also to
promote ascending aortic dilatation or aneurysm (Burks et al., 1998; Perloff, 2003; Roberts,
1970). However, it remains unclear whether these aortic manifestations are genetically
determined or represent a byproduct of mechanical stress, given that aortic dilatation is
indistinct among regurgitant, stenotic and functionally normal bicuspid aortic valves (Hahn
et al., 1992). Emerging evidence supports increased proteolytic activity in the aortic valve and
adjacent areas including the aorta that may enhance the remodeling processes (Aikawa et al.,
2007b).
Valvular calcification in the early stages causes aortic sclerosis, which predicts increased risks
for cardiovascular morbidity and mortality (Otto et al., 1999). As the process progresses, the
aortic valve orifice narrows while the valve anatomy and function become gradually distorted
to produce valvular aortic stenosis with or without regurgitation, myocardial hypertrophic
response, myocardial fibrosis, heart failure, and hemodynamic instability (Dweck et al., 2012).
In recent years, the concept of degeneration in the pathogenesis of calcific aortic valve disease
has been superseded by that of phenotypic modulation recapitulating embryonic develop‐
ment, angiogenesis, acquired and innate immune activation, wound healing and bone
formation (Hakuno et al., 2009).
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4. Acquired aortic valve disease
4.1. Aortic valve calcification and systemic inflammation
Aortic valve sclerosis has been estimated to affect at least 20% of adults over 65 years of
age in the general  population (Lindroos et  al.,  1993;  Stewart  et  al.,  1997).  Calcific  aortic
valve disease represents a continuum of maladapted calcification in the aortic valve aris‐
ing from active inflammatory and oxidative processes (Kaden et al., 2004; New and Aika‐
wa,  2011;  Towler,  2008),  as  well  as  a  shift  in  the  valve  interstitial  phenotype  from
chondrogenic to osteogenic. Early calcification of the aortic valve leads to increased valve
leaflet  thickness  and  stiffness  in  a  condition  termed  aortic  valve  sclerosis  (Otto  et  al.,
1999).  Continuation of the inflammatory process propagates angioneogenesis and biomi‐
neralization,  leading  to  formation  of  calcium  nodules  that  distort  valve  geometry  and
function,  culminating  in  outflow-limiting  aortic  stenosis  with  or  without  regurgitation
(Dweck et al., 2012; Rajamannan et al., 2011). Conditions that promote systemic inflamma‐
tion, such as atherosclerosis, dyslipidemia and diabetes mellitus, have been shown to ex‐
acerbate the development of calcific aortic valve disease (Rajamannan et al., 2011). While
statins may stabilize atheromatous plaques,  reduce vascular calcification and clinical  ad‐
verse  outcomes,  they have unfortunately not  been shown to benefit  calcific  aortic  valve
disease in disease progression or patient outcomes (Chan et al., 2010; Cowell et al., 2005;
Rossebo et al., 2008).
Studies exploring Notch signaling beyond congenital disorders and developmental biology
identified Dll4 in macrophage-mediated inflammation (Fung et al., 2007). Recently, Fukuda
and colleagues demonstrated that blockade of Dll4-Notch signaling using anti-Dll4 monoclo‐
nal antibody decreased BMP2, a central regulator of osteogenesis and bone mineralization
(Fukuda et al., 2012), in line with other studies showing reduced aortic valve calcification with
BMP2 knockdown by siRNA (Nigam and Srivastava, 2009), and the proinflammatory cytokine,
TNF-α, accelerated BMP2-mediated calcification of human aortic valve interstitial cells from
patients with calcific aortic valve stenosis (Yu et al., 2011). BMP2 mediates aortic valve
calcification via Runx2 (Osf2/Cbfa1), a transcriptional activator of osteoblast development or
gene expression (Ducy et al., 1997; Kaden et al., 2004; Mohler et al., 2001), and is suppressible
by activation of Notch1 via Hey (HRT) (Acharya et al., 2011; Nigam and Srivastava, 2009).
Moreover, the marked attenuation of aortic valvular calcification and stenosis through the
blockade of angiogenesis-promoting Dll4 in a mouse model of hypercholesterolemia (Figure
2) also supports the current theory that angioneogenesis is a crucial stage in the natural history
of calcific aortic valve disease (Dweck et al., 2012), recapitulating cardiogenesis and valve
development (de la Pompa and Epstein, 2012; van den Akker et al., 2012). Thus, Dll4 critically
bridges inflammation and angioneogenesis to osteogenesis in calcific aortic valve disease
(Fukuda et al., 2012). These effects are probably independent of Notch 1 (Nus et al., 2011), since
activation of the receptor presumably leads to inhibition of valve calcification (Acharya et al.,
2011), whereas evidence on the benefits of Dll4 blockade (i.e. interruption of Dll4–Notch
signaling) suggests that a Notch receptor other than Notch1, when activated, potentiates the
development and progression of valve calcification. A shift in the Notch receptor:ligand ratio
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and/or the DLL:Jagged (Notch ligands) ratio may plausibly alter the cell-to-cell signalling
strength and modality in cis and/or in trans, thus, modifying the final functional outcome. Much
work remains to be done to fully delineate the mechanisms through which anti-Dll4 antibody
exert inhibitory effects on inflammation and calcification.
 
Figure 2. Ex vivo mapping using fluorescence reflectance imaging to grossly visualize the biomineralization of the
hearts and vessels of atherosclerosis-prone (low-density lipoprotein receptor-deficient, Ldlr–/–) animals fed a hypercho‐
lesterolemic diet, and independently treated with IgG isotype control or anti-Dll4 monoclonal antibody (Dll4 Ab). 750-
nm CLIO750 nanoparticles were used to image macrophages, and 680-nm VisEn OsteoSense680 was used for the
detection of osteogenic activity (top and bottom rows). Decreased osteogenic activity in the anti-Dll4 monoclonal an‐
tibody treated specimen is visualized using alkaline phosphatase (ALP) staining (middle row). Adapted from Fukuda
and colleagues (Fukuda et al., 2012).
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5. Clinical implications
Calcific aortic valve disease in individuals with severe aortic stenosis can progress quickly
after presentation with symptoms, usually portending limited short-term survival (Turina et
al., 1987). Clinical trials on medical therapy including statins have found little benefit and
utility in forestalling disease progression, with no demonstrated impact on survival. Since the
evidence suggests that inflammatory cells, particularly macrophages, play a crucial role in
calcification, anti-inflammatory therapies may prevent development of arterial and valvular
calcification. We and others have demonstrated that lipid lowering reduces inflammation
(Aikawa et al., 1998; Aikawa et al., 2001; Chu et al., 2012; Libby and Aikawa, 2002; Libby et al.,
2011). However, clinical trials (e.g. SALTIRE, SEAS, etc.) have failed to demonstrate that lipid
lowering attenuates development of aortic stenosis. Preclinical findings suggest that macro‐
phage accumulation precedes calcific changes in arteries and valves while lesions with
advanced calcification are often unassociated with macrophages (Aikawa et al., 2007a; Aikawa
et al., 2007b). This may suggest that anti-inflammatory therapies need to be initiated early
(Aikawa and Otto, 2012), and thus clinical trials involving patients who had been diagnosed
with aortic stenosis due to advanced calcification did not show substantial benefits of lipid
lowering therapy. To establish more effective therapies, it is crucial to better understand the
complex mechanisms for aortic valve calcification. To identify individuals with subclinical
aortic valve calcification and those with high probability or propensity of developing severe
aortic valvular stenosis, methods for early detection of calcific changes (e.g., molecular
imaging, biomarkers) need to be developed. National Institutes of Health of the United States
of America has formed the Working Group of Calcific Aortic Valve Disease to facilitate basic
research on this devastating global health threat and initiated federal funding (Rajamannan et
al., 2011).
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